GlobeNewswire by notified

DOVRE GROUP TRADING STATEMENT JANUARY 1 – SEPTEMBER 30, 2023

Share

Dovre Group Plc                Stock exchange release        October 26, 2023, at 8.45 a.m.  

DOVRE GROUP TRADING STATEMENT JANUARY 1 – SEPTEMBER 30, 2023


Dovre Group Plc issues today a trading statement for the three months ended on September 30, 2023.The figures presented in this trading statement are not audited. Last year’s corresponding period in parentheses. 

July – September 2023 

  • Net sales EUR 52.8 (59.7) million – decrease of -11.6%.  
    • Project Personnel: net sales EUR 28.8 (22.5) million – increase of 28.2%.  
    • Consulting: net sales EUR 3.5 (4.4) million – decrease of -19.7%.  
    • Renewable Energy: net sales EUR 20.5 (32.9) million – decrease of -37.8%.  
  • EBITDA EUR 2.9 (3.2) million – decrease of -7.2%.  
  • Operating profit EUR 2.7 (3.0) million – decrease of -12.1%.   
  • Profit before tax EUR 2.1 (2.9) million – decrease of -26.2%.  
  • Profit for the shareholders of the parent company EUR 1.3 (1.9) million – decrease of -31.6%.  
  • Earnings per share EUR 0.012 (0.018) – decrease of -32.6%.  
  • Net cash flow from operating activities EUR -3.3 (0.6) million.  

January – September 2023 

  • Net sales EUR 145.9 (154.9) million – decrease of -5.8%.  
    • Project Personnel: net sales EUR 79.5 (67.6) million – increase of 17.6%.  
    • Consulting: net sales EUR 12.6 (13.3) million – decrease of -5.5%.  
    • Renewable Energy: net sales EUR 53.8 (73.9) million – decrease of -27.2%.  
  • EBITDA EUR 6.6 (7.0) million – decrease of -4.8%.
  • Operating profit EUR 5.9 (6.3) million – decrease of -6.7%.   
  • Profit before tax EUR 4.9 (6.0) million – decrease of -18.8%.  
  • Profit for the shareholders of the parent company EUR 3.1 (4.1) million – decrease of -24.0%. 
  • Earnings per share EUR 0.029 (0.039) – decrease of -25.6%.  
  • Net cash flow from operating activities EUR 3,8 (0.0) million.  


Outlook for 2023 unchanged (issued on 26 June 2023):

Dovre Group’s net sales in 2023 are expected to be in the range of 185 to 195 million Euros and the operating profit (EBIT) is expected to be above 7.0 million.   

ARVE JENSEN, CEO:

In Q3 2023, Dovre Group posted total net sales of EUR 52.8 million, reflecting an 11.6% decrease compared to the same period in 2022. Year-on-year fluctuations in foreign currency exchange rates, particularly the Norwegian krone, had an impact on the Group’s net sales in Q3. At fixed rates, the net sales decreased by 6.4%.

Our Project Personnel segment was the outstanding performer in Q3 and reported a remarkable 28.2% increase in net sales compared to Q3 2022. By contrast, the Consulting segment reported a 19.7% decrease and Renewable Energy experienced a 37.8% decrease in net sales during Q3 2023.

A ransom attack on our Norwegian operations in late September impacted our financial systems and operational directories. We have successfully recovered from this incident without interruption to our services and we used this opportunity to move our financial systems to be cloud-based. This will yield lower costs for the financial function in Norway starting from Q4/2023.

Despite challenges posed by the weak Norwegian currency and new labor legislation, our Project Personnel division maintained robust growth. Meanwhile, our Canadian operations remained active, particularly with a major biodiesel refinery project. In the Consulting sector, the comparison period in 2022 was at an all-time high, but we have since leveled down from that peak. This notwithstanding, the Norwegian consulting unit signed a new multi-year framework agreement with the Ministry of Finance.

The Finnish wind farm construction market's sluggish performance in 2023 affected Suvic’s operations throughout the year. However, Suvic had already diversified its scope in 2022 to encompass other renewable business areas, thus securing new projects such as the Fortum heat-exchange power plant in Kirkkonummi and an "early works contract" for two large wind farms in Sweden during Q3.

Varied performance between the three segments is a natural part of our business landscape. These fluctuations can be attributed to market cycles, project timelines, and related factors. They also highlight the need for continuous adaptability, prudent risk management, and strategic foresight. 


NET SALES

Net sales in Q3

In Q3, Dovre Group’s net sales decreased by -11.6% to EUR 52.8 (59.7) million.  

Project Personnel accounted for 54 (38) %, Consulting for 7 (7) %, and Renewable Energy for 39 (55) % of the Group’s net sales.

Project Personnel’s net sales increased by 28.2% to EUR 28.8 (22.5) million, while net sales for Consulting decreased by -19.7% to EUR 3.5 (4.4) million. Net sales in Renewable Energy were also down by -37.8% to 20.5 (32.9) million euros.  

Net sales by reporting segment

7–9


7–9


Change


1–9


1–9


Change


1–12
EUR million 20232022%20232022%2022
Project Personnel 28.8  22.5  28.2   79.567.6 17.6 90.6  
Consulting 3.5  4.4  -19.7  12.6 13.3 -5.5 18.2  
Renewable Energy 20.5  32.9  -37.8  53.8 73.9 -27.2 94.2  
Group total 52.859.7-11.6145.9154.9-5.8 203.0  

OPERATING PROFIT

Profitability in Q3

The Group’s EBITDA in Q3 decreased by -7.2% to EUR 2.9 (3.2) million. The Group’s operating profit decreased by -12.1% to EUR 2.7 (3.0) million. Project Personnel’s operating profit was EUR 1.7 (1.1) million, Consulting’s operating profit was EUR 0.4 (0.7) million and Renewable Energy’s operating profit was EUR 0.9 (1.4) million. In Renewable Energy, the weakened Q3 profitability year-on-year was attributable to the difference in portfolio of projects. The operating loss of the Group’s Other functions was -0.2 (-0.2) million.   

EBITDA

7–9


7–9


Change


1–9


1–9


Change

1–12
EUR million 20232022%20232022%2022
Project Personnel 1.8  1.2  59.0  4.2 3.4 21.6 4.7  
Consulting 0.4  0.7  -42.5  1.3 1.6 -19.5 2.5  
Renewable Energy 0.9  1.5  -36.2  1.7 2.4 -27.8 2.9  
Other Functions -0.2  -0.1  -39.2  -0.6 -0.4 -33.3 -0.7  
Unallocated * 0.0  0.0  159.3  0.0 -0.1 75.2 0.0  
Group total 2.93.2-7.2 6.6 7.0-4.8 9.5 


Operating profit

7–9


7–9


Change


1–9


1–9


Change

1–12
EUR million 20232022%20232022%2022
Project Personnel 1.7  1.1  53.7  3.8 3.2 20.0 4.3  
Consulting 0.4  0.7  -42.6  1.3 1.6 -19.0 2.5  
Renewable Energy 0.9  1.4  -43.9  1.6 2.3 -31.9 2.7  
Other Functions -0.2  -0.2  -34.2  -0.6 -0.5 -28.7 -0.7  
Unallocated * -0.1  -0.1  8.4  -0.2 -0.3 39.2 -0.3  
Group total 2.7  3.0-12.15.9 6.3 -6.7 8.5  

*Unallocated expenses include amortization of customer agreements and relations.

PERSONNEL

In Q3 2023, the average number of employees increased by 14.4% year-on-year. During January–September, Dovre Group employed an average of 833 people (789). The average number of employees during the period increased due to the organic growth of the Project Personnel and Renewable Energy business areas.  

On September 30, 2023, Dovre Group employed 900 (708) people, 746 (563) of whom were employed by Project Personnel, 95 (101) by Consulting, 57 (42) by Renewable Energy and 2 (2) by Other functions.   



Average number of personnel


7–9


7–9

Change


1–9


1–9


Change

1–12
20232022%20232022%2022
Project Personnel 723  619  16.8  682 653 4.4 642  
Consulting 93  99  -6.4  100 97 2.7 98  
Renewable Energy 54  42  28.6  49 36 34.5 38  
Other Functions 2  2  0.0  0.0 1  
Group total 87276214.4 833 7895.6 779
Personnel at period-end

30.9.


30.9.


Change


31.12.
20232022%2022
Project Personnel  746  563  32.6  583  
Consulting  95  101  -5.9  100  
Renewable Energy*  57  42  35.7  43  
Other Functions  2  2  0.0  2  
Group total 900 70827.2 728 

CASH POSITION

On September 30, 2023, the Group’s net debt was EUR -1.7 (1.3) million. The Group’s cash and cash equivalents totaled EUR 9.2 (7.9) million. The Group’s interest-bearing liabilities were EUR 7.5 (9.2) million, a total of EUR 5.8 (6.2) million of which were current and EUR 1.7 (3.0) million non-current.   

In January – September, net cash flow from operating activities totaled EUR 3.8 (0.0) million, which includes EUR 0.7 (-5.6) million change in working capital. The increase in working capital is mainly due to the decrease in the total amount of advance payments from projects in progress.   

In Espoo, October 26, 2023  

DOVRE GROUP PLC  
BOARD OF DIRECTORS  

For additional information, please contact:  

Dovre Group Plc  
Arve Jensen, CEO  
tel.  +47 90 60 78 11  
arve.jensen@dovregroup.com  


Distribution
Nasdaq Helsinki Ltd  
Major media  
www.dovregroup.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Lerøy Seafood Group ASA: Record revenue in 2023. Progress towards targets for 2025.28.2.2024 06:30:00 CET | Press release

RECORD REVENUE IN 2023. MAKING PROGRESS TOWARDS 2025 TARGETS 2023 marks the first year in Lerøy's history where revenue exceeds NOK 30 billion. Seafood's position among consumers remains strong. We continue to vigorously work towards developing the most efficient and sustainable value chain for seafood. I am proud of the work our employees do, while acknowledging that the past year has been challenging," says CEO Henning Beltestad. FOURTH QUARTER 2023 DEVELOPMENT In the fourth quarter of 2023, Lerøy delivered an operating profit before biomass adjustments of NOK 765 million. In Farming, we experienced challenges related to string jellyfish and lost feeding days in Lerøy Aurora and accelerated harvest in Lerøy Sjøtroll. In Wild Catch, earnings were approximately the same as the same period the year before. In the VAP S&D segment, there is positive development as previously communicated, as product prices has increased, reflecting the increased raw material costs, and we have gradually s

Lerøy Seafood Group ASA: Rekordomsetning i 2023. Fremgang mot mål for 2025.28.2.2024 06:30:00 CET | Pressemelding

REKORDOMSETNING I 2023 2023 er det første året i Lerøy sin historie at omsetningen overstiger NOK 30 mrd. Sjømatens posisjon hos konsumentene står sterkt. Vi fortsetter med full kraft arbeidet med å utvikle den mest effektive og bærekraftige verdikjeden for sjømat. Jeg er stolt av den jobben vi og våre ansatte gjør, samtidig som vi erkjenner at året som har gått har vært utfordrende, sier konsernleder Henning Beltestad. UTVIKLING I FJERDE KVARTAL 2023 I fjerde kvartal 2023 leverte Lerøy et driftsresultat før biomassejusteringer på NOK 765m. I Havbruk opplevde vi utfordringer knyttet til perlesnor-maneter og tap av fôringsdager i Lerøy Aurora og fremskyndet slakting i Lerøy Sjøtroll. Innen Villfangst ble inntjeningen om lag som samme periode året før. I nedstrømsvirksomhetene i segmentet VAP S&D er det som tidligere kommunisert positiv utvikling ettersom produktprisen nå i større grad reflekterer de økte råvarekostnadene, og vi gradvis har lykkes med operasjonelle forbedringer. Styret i

BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)27.2.2024 21:52:04 CET | Press release

Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin (rhu-pGSN) for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955). The study, A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections is being conducted under a contract with BARDA’s Division of Research, Innovation, and Ventures (DRIVe), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Approximately 80 sites

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons27.2.2024 21:42:24 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameAnthony Pagano2.Reason for the notificationa)Position/statusExecutive Vice President & Chief Financial Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction pla

Capital Increase in Genmab as a Result of Employee Warrant Exercise27.2.2024 21:40:01 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 27, 2024 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 7,325 shares at DKK 1,025.00, 19,631 shares at DKK 1,032.00, 2,473 shares at DKK 1,050.00, 1,422 shares at DKK 1,161.00, 40 shares at DKK 1,334.50, 1,036 shares at DKK 1,362.50, 6,660 shares at DKK 1,402.00, 129 shares at DKK 1,408.00, and 9,713 shares at DKK 1,615.00. Proceeds to the company are approximately DKK 58.7 million. The increase corresponds to approximately 0.07% of the company's share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as

HiddenA line styled icon from Orion Icon Library.Eye